Companion Spine develops minimally invasive diagnostic and therapeutic solutions targeting degenerative disc disease (DDD) and lumbar spinal stenosis (LSS). Its portfolio includes technologies and assets acquired in September 2020 from Medtronic, comprising regulatory and clinical property, six patent families covering more than 140 patents, and instrument and implant inventory. Key products include the CE‑marked DIAM implant (FDA Breakthrough Device designation, Oct 2021), the APERIUS intervertebral implant for percutaneous treatment of lumbar stenosis, and the DISC ANALYZER diagnostic technology. The company plans U.S. and international commercialization of these devices, with U.S. launches expected in 2023–2024, and already maintains a U.S. subsidiary. Companion Spine emphasizes early, precise, minimally invasive diagnostics and reversible interventional treatments intended to avoid irreversible spinal fusion. The company is pursuing partnerships and potential acquisitions to broaden its portfolio.

Total raised

$55M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2022